Testing effectiveness (Phase 2)Ended earlyNCT03233724
What this trial is testing
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-Small Cell Lung Cancer+2 more
National Cancer Institute (NCI) 9